In The Spotlight


Epalinges, Switzerland-based ADC Therapeutics announced the pricing of initial public offering of 12.25 million shares at $19.00 per share, above the expected range of $16 to $18 per share. The company has originally filed to sell 7.355 million shares of its common stock. The company said that...

adctherapeutics may14 Epalinges, Switzerland-based ADC Therapeutics is scheduled to list its stock on the NYSE, under the symbol 'ADCT', on May 14, 2020. This is the second attempt of the company to go public. ADC Therapeutics, which is a spinoff from Spirogen Ltd., had withdrawn its IPO filing in September 2019, citing adverse market conditions.

novavax may12 Shares of Novavax Inc. (NVAX) jumped 30 percent in Monday's regular trading and gained nearly 40 percent in after-hours, following significant progress in the Company's influenza and COVID-19 vaccine programs and increased funding from the Coalition for Epidemic Preparedness Innovations.

krystal may07 Shares of Krystal Biotech Inc. (KRYS) have now more than doubled in value since touching a 52-week low of $22.02 on June 14, 2019.

ayalapharmaipo may06 Israel-based Ayala Pharmaceuticals is slated to debut on the Nasdaq Global Select Market, under the symbol 'AYLA', on May 7, 2020.

relmada april28 Shares of Relmada Therapeutics Inc. (RLMD) have gained 19 percent so far this year and trade around $37.

bioxcel april17 Shares of BioXcel Therapeutics Inc. (BTAI) have gained nearly 86 percent over the last 1 month as the Company gears up for reporting trial results of one of its most advanced clinical development programs BXCL501.

Shares of Seattle Genetics Inc. (SGEN), which touched an all-time high of $128 on April 7, 2020, have since lost 6 percent of their value and trade around $120.

kadmon april13 The Company we are profiling today is also developing a drug for cGVHD - Kadmon Holdings Inc. (KDMN), and the drug candidate in focus is KD025.

Follow RTT